NCT05367765View on ClinicalTrials.gov

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

2,400

Participants

Timeline

Start Date

April 30, 2022

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions
CML, Chronic Phase
Interventions
DRUG

Flumatinib

Flumatinib 600mg orally daily

DRUG

Imatinib

Imatinib 400mg orally daily (Reference drug instructions)

Trial Locations (1)

201203

Institute of Hematology and Oncology, Harbin The First Hospital, Harbin

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

NCT05367765 - A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | Biotech Hunter | Biotech Hunter